Dean Fergusson profile picture

Contact Information

Dean Fergusson, PhD, MHA, FCAHS

dafergusson@ohri.ca

Administrative Coordinator:
Jodi Peters
613-737-8899 x79842
jpeters@ohri.ca

ORCID logo https://orcid.org/0000-0002-3389-2485

Dean Fergusson

Senior Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Director, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Full Professor, Departments of Medicine, Surgery, & the School of Epidemiology and Public Health
University of Ottawa
Endowed Chair, Clinical Epidemiology Program
Ottawa Hospital Research Institute/University of Ottawa
Scientific Lead, Ontario SPOR SUPPORT Unit
Government of Ontario and the Canadian Institutes of Health Research

Research Interests

I have focused my research contributions in the following areas:

1) transfusions and transfusion alternatives

2) patient-oriented research methods and practice

3) methodological research into the ethics, design and analysis of randomized trials

4) evidence-informed approaches to improve bench to bedside translation

Brief Biography

Dr. Fergusson is a Senior Scientist & Director, Clinical Epidemiology Program, at the Ottawa Hospital Research Institute. He is also a Full Professor, Departments of Medicine, Surgery, & of the School of Epidemiology and Public Health, University of Ottawa. Dr. Fergusson holds the position of Endowed Chair, OHRI/uOttawa, Clinical Epidemiology Program and is the Scientific Lead of the Ontario SPOR SUPPORT Unit (OSSU).

He holds a PhD (Honours) in Epidemiology and Biostatistics from McGill University and a Master of Health Administration from the University of Ottawa. Dr. Fergusson’s clinical research interests are mainly in the field of transfusion medicine with a focus on transfusion alternatives and the effectiveness of blood products. His research interests also extend to the methodology and ethics of clinical trials and systematic reviews. Dr. Fergusson is a Principal Investigator on the national Accelerating Clinical Trials (ACT) Consortium and CANTRAIN Clinical Trials Training Platform, both funded by CIHR. He was also the co-lead of the Rethinking Clinical Trials (REaCT) Program which performs practical patient-focused research that ensures that patients receive optimal, safe, cost-effective treatment. Dr. Fergusson is a principal investigator on a number of large, peer-reviewed clinical trials in transfusion medicine including “An innovative Trial Assessing Donor Sex on Recipient Mortality (iTADS), “Blood Conservation Using Antifibrinolytics: Randomized Trial in High-Risk Cardiac Surgery (BART)”, Age of Red Blood Cells in Premature Infants (ARIPI), and “Age of Blood Evaluation (ABLE)”. Dr. Fergusson has contributed over 700 full journal articles to the medical literature.

Selected Publications

  1. Chassé M, Tinmouth A, English SW, Acker JP, Wilson K, Knoll G, Shehata N, van Walraven C, Forster AJ, Ramsay T, McIntyre LA, Fergusson DA. Association of Blood Donor Age and Sex With Recipient Survival After Red Blood Cell Transfusion. JAMA Intern Med. 2016 Sep 1;176(9):1307-14
  2. Fergusson DA, Hébert P, Hogan DL, Lebel L, Rouvinez-Bouali N, Smyth JA, Sankaran K, Tinmouth A, Blajchman MA, Kovacs L, Lachance C, Lee S, Walker CR, Hutton B, Ducharme R, Balchin K, Ramsay T, Ford JC, Kakadekar A, Ramesh K, Shapiro S. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: The ARIPI Randomized Trial. JAMA, 2012 Oct. 10;308(14)1443-51.
  3. Mazer CD, Whitlock RP, Fergusson DA, Hall J, Belley-Cote E, Connolly K, Khanykin B, Gregory AJ, de Médicis É, McGuinness S, Royse A, Carrier FM, Young PJ, Villar JC, Grocott HP, Seeberger MD, Fremes S, Lellouche F, Syed S, Byrne K, Bagshaw SM, Hwang NC, Mehta C, Painter TW, Royse C, Verma S, Hare GMT, Cohen A, Thorpe KE, Jüni P, Shehata N; TRICS Investigators and Perioperative Anesthesia Clinical Trials Group. Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery. N Engl J Med. 2017 Nov 30;377(22):2133-2144.
  4. Lacroix J, Hébert PC, Fergusson DA, Tinmouth A, Cook DJ, Marshall JC, Clayton L, McIntyre L, Callum J, Turgeon AF, Blajchman MA, Walsh TS, Stanworth SJ, Campbell H, Capellier G, Tiberghien P, Bardiaux L, van de Watering L, van der Meer NJ, Sabri E, Vo D; ABLE Investigators and the Canadian Critical Care Trials Group. Age of Transfused Blood in Critically Ill Adults. N Engl J Med. 2015; 372(15):1410-8
  5. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008; 358(22): 2319-31.

Diseases, conditions and populations of interest





Research and clinical approaches